RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Fulcrum Therapeutics Stock

Fulcrum Therapeutics Stocks 2024

Fulcrum Therapeutics Stocks

61.31 M

Ticker

FULC

ISIN

US3596161097

In 2024, Fulcrum Therapeutics had 61.31 M outstanding stocks, a 0% change from the 61.31 M stocks in the previous year.

The Fulcrum Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e61.31
2028e61.31
2027e61.31
2026e61.31
2025e61.31
2024e61.31
202361.31
202244.99
202135.36
202025.35
201922.65
201822.29
201722.29

Fulcrum Therapeutics shares outstanding

The number of shares was Fulcrum Therapeutics in 2023 — This indicates how many shares 61.31 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Fulcrum Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Fulcrum Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Fulcrum Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Fulcrum Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Fulcrum Therapeutics Aktienanalyse

What does Fulcrum Therapeutics do?

Fulcrum Therapeutics Inc is a biotech company based in Cambridge, Massachusetts, that focuses on developing drugs for treating rare diseases. It was founded in 2015 and has achieved significant milestones since then. The business model of Fulcrum Therapeutics involves utilizing advanced technologies and scientific knowledge to develop new therapies for rare diseases. The company collaborates closely with experts in the field to make groundbreaking discoveries and develop drugs that can improve patients' lives. Fulcrum Therapeutics specializes in three main areas: neuromuscular diseases, rare genetic diseases, and cancer. The company aims to understand the underlying causes of these diseases and develop targeted therapies that meet the specific needs of patients. In terms of neuromuscular diseases, Fulcrum Therapeutics has developed a promising technology called the Product Platform, which aims to better understand the genetic cause of muscle diseases. By using artificial intelligence and large datasets, this technology can help develop new therapies specifically tailored to the needs of patients with muscle diseases. For rare genetic diseases, Fulcrum Therapeutics is working on developing therapies that target the underlying genetic defects. An example is Huntington's disease, a genetic disorder that affects the nervous system and leads to progressive motor impairments and dementia. Fulcrum is developing drugs that specifically target the genetic defect causing Huntington's disease, aiming to enable more effective treatment. In the field of cancer, Fulcrum Therapeutics is working on new immunotherapies that utilize the body's immune system to fight the spread of cancer cells. The company primarily utilizes a T-cell technology for this purpose. To achieve these goals, the company collaborates closely with academic institutions, medical experts, and other industry partners. It has quickly built an experienced and interdisciplinary team of scientists, developers, and executives focused on developing innovative therapies for treating rare diseases. In conclusion, Fulcrum Therapeutics Inc is a company with a unique and promising business model. The company is dedicated to developing new therapies for patients with rare diseases by utilizing innovative technologies and scientific knowledge. If successful, Fulcrum Therapeutics' research has the potential to improve the lives of millions of people worldwide. Fulcrum Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Fulcrum Therapeutics's Shares Outstanding

Fulcrum Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Fulcrum Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Fulcrum Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Fulcrum Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Fulcrum Therapeutics stock

How many stocks are there of Fulcrum Therapeutics?

The current number of stocks of Fulcrum Therapeutics is 61.31 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Fulcrum Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Fulcrum Therapeutics evolved in recent years?

The number of shares of Fulcrum Therapeutics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Fulcrum Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Fulcrum Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Fulcrum Therapeutics pay?

Over the past 12 months, Fulcrum Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Fulcrum Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Fulcrum Therapeutics?

The current dividend yield of Fulcrum Therapeutics is .

When does Fulcrum Therapeutics pay dividends?

Fulcrum Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Fulcrum Therapeutics?

Fulcrum Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Fulcrum Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Fulcrum Therapeutics located?

Fulcrum Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Fulcrum Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fulcrum Therapeutics from 9/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/28/2024.

When did Fulcrum Therapeutics pay the last dividend?

The last dividend was paid out on 9/28/2024.

What was the dividend of Fulcrum Therapeutics in the year 2023?

In the year 2023, Fulcrum Therapeutics distributed 0 USD as dividends.

In which currency does Fulcrum Therapeutics pay out the dividend?

The dividends of Fulcrum Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Fulcrum Therapeutics

Our stock analysis for Fulcrum Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fulcrum Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.